利福喷汀、异烟肼和莫西沙星对结核分枝杆菌的体外抗生素后效应
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
作者信息
Chan Chiu-Yeung, Au-Yeang Carrie, Yew Wing-Wai, Leung Chi-Chiu, Cheng Augustine F B
机构信息
Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories.
出版信息
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
Abstract
Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.
摘要
使用放射性培养系统研究了利福喷汀、异烟肼和莫西沙星对结核分枝杆菌ATCC 27294的抗生素后效应（PAEs）。在单独使用的药物中，20毫克/升的利福喷汀产生的PAE最长（104小时）。利福喷汀加异烟肼、利福喷汀加莫西沙星以及异烟肼加莫西沙星的组合产生的PAE分别为136.5、59.0和8.3小时。
相似文献
1
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.利福喷汀、异烟肼和莫西沙星对结核分枝杆菌的体外抗生素后效应
Antimicrob Agents Chemother. 2004 Jan;48(1):340-3. doi: 10.1128/AAC.48.1.340-343.2004.
2
Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.莫西沙星对结核分枝杆菌对数生长期和稳定期培养物的杀菌活性。
J Chemother. 2009 Apr;21(2):127-34. doi: 10.1179/joc.2009.21.2.127.
3
Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.结核分枝杆菌在中性pH值的低氧环境中被利福平及利福喷汀选择性杀灭。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02296-16. Print 2017 Mar.
4
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.加替沙星对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5. doi: 10.1128/AAC.46.4.1022-1025.2002.
5
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.在小鼠模型中，每日服用利福喷丁可在三个月或更短时间内治愈结核病。
PLoS Med. 2007 Dec;4(12):e344. doi: 10.1371/journal.pmed.0040344.
6
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.莫西沙星和加替沙星在结核分枝杆菌持续感染酸性模型中的研究
J Chemother. 2006 Dec;18(6):617-23. doi: 10.1179/joc.2006.18.6.617.
7
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.每周一次的利福喷汀和莫西沙星联合方案对小鼠结核分枝杆菌的疗效。
Antimicrob Agents Chemother. 2001 Dec;45(12):3482-6. doi: 10.1128/AAC.45.12.3482-3486.2001.
8
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.结核分枝杆菌北京基因型的药物敏感性及其与 MDR-TB 的关系。
Emerg Infect Dis. 2012 Apr;18(4):660-3. doi: 10.3201/eid1804.110912.
9
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.苯并噻嗪酮先导化合物 BTZ043 对结核分枝杆菌的体外联合研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5790-3. doi: 10.1128/AAC.01476-12. Epub 2012 Aug 27.
10
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?在基于利福喷汀的实验性结核病治疗方案中使用异烟肼还是莫西沙星？
Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.
引用本文的文献
1
Next-generation rifamycins for the treatment of mycobacterial infections.用于治疗分枝杆菌感染的新一代利福霉素类药物。
Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2423842122. doi: 10.1073/pnas.2423842122. Epub 2025 May 1.
2
Toward a Bactericidal Oral Drug Combination for the Treatment of Lung Disease.研发用于治疗肺部疾病的杀菌性口服药物组合。
ACS Infect Dis. 2025 Apr 11;11(4):929-939. doi: 10.1021/acsinfecdis.4c00948. Epub 2025 Apr 1.
3
and Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections.且格帕沙星对耐药分枝杆菌感染的活性。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0056422. doi: 10.1128/aac.00564-22. Epub 2022 Nov 29.
4
Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.基于模型的结核分枝杆菌感染小鼠模型中spectinamide 1810 的暴露-反应评估。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0174420. doi: 10.1128/AAC.01744-20. Epub 2021 Aug 23.
5
Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis.利用自发光结核分枝杆菌快速、高效且无损的检测方法对抗结核化合物进行分析。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0028221. doi: 10.1128/AAC.00282-21.
6
All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era.所有的不依从都是一样的，但有些不依从比其他的更“一样”？数字时代的结核病。
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00315-2020. eCollection 2020 Oct.
7
Kinetic Analyses of the Siderophore Biosynthesis Inhibitor Salicyl-AMS and Analogues as MbtA Inhibitors and Antimycobacterial Agents.作为 MbtA 抑制剂和抗分枝杆菌药物的铁载体生物合成抑制剂水杨酰基-AMS 及其类似物的动力学分析。
Biochemistry. 2019 Feb 12;58(6):833-847. doi: 10.1021/acs.biochem.8b01153. Epub 2019 Jan 10.
8
A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.莫西沙星治疗药物敏感型结核病的综述
J Clin Pharmacol. 2017 Nov;57(11):1369-1386. doi: 10.1002/jcph.968. Epub 2017 Jul 24.
9
A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.含利福喷丁的吸入式三联抗生素制剂，用于快速治疗结核感染。
Pharm Res. 2014 May;31(5):1239-53. doi: 10.1007/s11095-013-1245-7. Epub 2013 Nov 16.
10
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.随机临床试验：新痰阳性肺结核患者三联 4 个月莫西沙星或加替沙星方案治疗。
PLoS One. 2013 Jul 3;8(7):e67030. doi: 10.1371/journal.pone.0067030. Print 2013.
本文引用的文献
1
Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.口服莫西沙星和克拉霉素的单剂量及多剂量药代动力学，以及血清、唾液和粪便中的浓度。
Scand J Infect Dis. 2002;34(12):898-903. doi: 10.1080/0036554021000026963.
2
Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.氟喹诺酮类药物对耐利福平结核分枝杆菌群体的杀菌活性。
Antimicrob Agents Chemother. 2003 Feb;47(2):653-7. doi: 10.1128/AAC.47.2.653-657.2003.
3
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.利福喷汀与异烟肼每周一次对比利福平与异烟肼每周两次用于治疗HIV阴性患者的药物敏感型肺结核：一项随机临床试验
Lancet. 2002 Aug 17;360(9332):528-34. doi: 10.1016/s0140-6736(02)09742-8.
4
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.一项关于利福喷汀600毫克、900毫克和1200毫克联合异烟肼在结核病治疗延续期耐受性的前瞻性、随机、双盲研究。
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526-30. doi: 10.1164/rccm.200201-047OC.
5
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.利福喷汀与异烟肼用于6个月疗程的继续期。5年最终报告：各项指标的预后价值
Int J Tuberc Lung Dis. 2002 Jan;6(1):3-10.
6
Postantibiotic effects of antituberculosis agents alone and in combination.抗结核药物单独及联合使用后的抗生素后效应。
Antimicrob Agents Chemother. 2001 Dec;45(12):3631-4. doi: 10.1128/AAC.45.12.3631-3634.2001.
7
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.每周一次的利福喷汀和莫西沙星联合方案对小鼠结核分枝杆菌的疗效。
Antimicrob Agents Chemother. 2001 Dec;45(12):3482-6. doi: 10.1128/AAC.45.12.3482-3486.2001.
8
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.利福霉素类抗菌药物的比较药代动力学和药效学
Clin Pharmacokinet. 2001;40(5):327-41. doi: 10.2165/00003088-200140050-00002.
9
Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.铁补充剂对新型8-甲氧基氟喹诺酮类药物莫西沙星在人体口服生物利用度的影响。
Clin Pharmacokinet. 2001;40 Suppl 1:57-62. doi: 10.2165/00003088-200140001-00008.
10
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.食物对健康男性志愿者单次口服400mg莫西沙星药代动力学的影响。
Clin Pharmacokinet. 2001;40 Suppl 1:19-25. doi: 10.2165/00003088-200140001-00003.
Zotero 插件